

Ghrelin is a peptide hormone with a strong stimulatory effect on growth hormone (GH) secretion. Ghrelin was originally isolated from the rat stomach as an endogenous secretagogue for the growth hormone secretagogue receptor (GHS-R). Although the first compounds of the group of growth hormone secretagogues were synthesized already in 1997, the isolation of the GHS-R and ghrelin is a matter of the last decade.

Our study was aimed at the determination of the physiological role of endogenous ghrelin in GH secretion in certain pathological conditions and its associations with the GH/IGF-1 axis compounds. Our study was the first one detecting also active ghrelin concentrations. We assumed, that ghrelin secretion is affected by the GH secretory state.

In patients with acromegaly we expected low ghrelin concentrations (hypothesis 1) and in patients with GHD we presumed, that ghrelin concentrations will be elevated (hypothesis 2) in comparison with healthy subjects as an effect of the negative feedback regulation by GH. Our findings however did not support these hypotheses, active and total ghrelin concentrations did not differ between patients and healthy controls. These data do not support an important role for ghrelin in GH secretion in these conditions as well as the existence of a negative feedback regulation between these hormones.

Ghrelin production was also found in the kidney. Therefore we assumed, that in case of renal failure ghrelin concentrations will be decreased due to its diminished production and due to the supposed negative feedback regulation by elevated GH concentrations (hypothesis 3). Again we confirmed neither our hypothesis, nor the existence of a negative feedback regulation between ghrelin and GH. It is probably the impaired clearance and/or metabolism of ghrelin in the kidney in renal failure, which is responsible for high ghrelin concentrations.

Acylated ghrelin is the most potent stimulator of GH secretion in vitro as well as in vivo, but the data available so far do not support its unique role in GH secretion as well as the existence of a negative feedback regulation between ghrelin and GH. Even the total absence of ghrelin in experiments on laboratory animals does not cause any changes in body composition and concentrations of GH/IGF-1 axis compounds. This is a result of compensatory processes, which substitute for ghrelin functions in the organism. Ghrelin is together with GHRH, somatostatin and a negative feedback regulation by IGF-1 only one of regulators of GH secretion.

This situation is probably preserved also in case of acromegaly and GHD, which is supported by our results and observations of another authors. Ghrelin concentrations are in these conditions not affected by the secretion of GH and their regulation is more complex. It includes chronic nutritional

state and the degree of adiposity in case of total ghrelin, and some so far unknown mechanisms in case of active ghrelin. On the other hand we can not exclude a possible role of ghrelin in GH secretion in case of renal failure, although the main mechanism, which is causing the elevation of GH and ghrelin concentrations in this condition is the impairment of clearance of both compounds. Problematic in the study of physiological functions of ghrelin in connection with the GH/IGF-I axis is the determination of ghrelin concentrations locally in hypothalamus/pituitary gland. Plasma concentrations of ghrelin may not reflect its concentrations in the hypothalamus/pituitary gland, where the role of ghrelin in GH secretion and the existence of a negative feedback regulation between ghrelin and GH may exist and further research is needed to confirm or exclude this hypothesis. Based on many observations it is possible to conclude, that the total ghrelin concentrations are affected by acute and chronic changes of nutritional state and by insulin concentrations. Our results however do not support the view, that similar regulatory mechanisms are involved in case of active ghrelin concentrations. Total ghrelin concentrations correlate positively with BMI and body fat mass, are decreased in obese and elevated in lean or cachectic subjects. The normalization of body weight leads to the normalization of total ghrelin concentrations and a restoration of the diurnal rhythm of ghrelin. Exogenously administered ghrelin leads in rodents to the stimulation of food ingestion and to weight gain, due to the increase in fat tissue. It decreases fat utilization and favors the utilization of saccharides as the main metabolic substrate in energetic metabolism. This effect of ghrelin seems to be independent of GH activities, since GH stimulates energy expenditure and decreases the amount of fat tissue due to the stimulation of lipolysis. The orexigenic and anabolic effects of ghrelin might represent an adaptation mechanism, which completes the effects of GH and ensures metabolic substrate for growth. Insulin is one of the most important regulators of ghrelin secretion. Many experiments showed negative correlations between ghrelin and insulin concentrations, hyperinsulinaemia had been shown to lower ghrelin concentrations. Although the relationship between both hormones is not understood in detail so far, it is plausible, that insulin directly or indirectly mediates the effect of nutrition on actual energy state on plasma ghrelin concentrations and vice versa. The decrease of insulin concentrations in starving leads to the elevation of ghrelin concentrations, while postprandial hyperinsulinaemia causes

an opposite effect. Chronic hyperinsulinism in obese subjects and low insulin concentrations in lean

and cachectic individuals might affect ghrelin concentrations in chronic nutritional changes by the

same mechanism. Reciprocally hyperghrelinemia in starving might decrease insulin synthesis and by

this mechanism maintain glucose concentrations in normal range, and postprandial hyperinsulinemia

might be the effect of a decrease in ghrelin secretion.

After the discovery of ghrelin it was primarily thought, that ghrelin could be a key factor causing simple obesity in man. But studies in obese individuals have shown, that its concentrations are

suppressed in obesity and elevated in lean and cachectic subjects. We suppose, that this is an effect of

a negative feedback regulation between ghrelin and insulin, when ghrelin secretion is suppressed by elevated insulin concentrations. Our own results let us presume, that a different situation occurs in

case of pathologic overproduction of ghrelin, insusceptible to a negative feedback regulation.

Exogenously administered ghrelin exerts orexigenic effects and leads to fat accumulation in laboratory

animals. Also in patients with a GIT tumor secreting ghrelin (ghrelinoma) and in patients with Prader-

Willy syndrome, where high ghrelin concentrations are probably caused by autonomous secretion of

ghrelin in central nervous system, there are elevated ghrelin concentrations associated with a high

BMI and body fat content. Our patients with renal failure had increased concentrations of active

ghrelin, probably due to an impaired clearance in the kidney. These patients had a high body fat

content at the same time and ghrelin concentrations correlated positively with body fat content.

Elevated concentrations of active ghrelin might therefore play a role in the etiopathogenesis of fat

tissue formation. Ghrelin thus could have diabetogenic effects due to an increase in gluconeogenesis

and due to a suppression of insulin production, which was proved in patients with ghrelinomas and in

laboratory animals.

At present ghrelin is considered by many authors to be an orexigenic signal from stomach, whose secretion is regulated by meal intake and insulin concentrations, which completes the proteosynthetic effects of GH. On the other hand in mice, where the ghrelin gene was knocked out, no

significant abnormalities were observed in food intake, body composition, size, growth rate or reproduction. Even in these animals exogenously administered ghrelin stimulates food intake, but its

endogenous total absence does not lead to anorexia. Therefore the orexigenic function of ghrelin is not

irreplaceable and other compensatory mechanisms substituting for this function are involved in the

regulation of food intake in ghrelin knocked out animals. In physiologic conditions ghrelin is not the main orexigenic factor. However in conditions associated with high ghrelin concentrations, which can not be down regulated by insulin (e.g. exogenous administration of ghrelin in animals, Prader-Willy syndrome, bulimia nervosa, ghrelinoma and according to our findings patients with renal insufficiency) ghrelin might exert adipogenic and diabetogenic effects.